CD274 and neoplasm: Oxaliplatin encapsulated in cellular vesicles resulted in immunogenic cell death, followed by DC vesicle presentation of tumor antigens to initiate T-cell responses. They also displayed synergistic antitumor effect when combined with anti-PD-L1 therapy.